[On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)].
The antihemagglutinin (AH) and antineuraminidase (AN) antibody response in 35 humans to a single vaccination with the aluminum oxide adsorbed influenza virus vaccine "Alorbat" was investigated. The vaccine contained the strains A/Hong Kong/1/68 (H3N2), A/Hong Kong/107/71 (H3N2), A/England/42/72 (H3N2) and B/Iowa/1/69. the rates of significant AH antibody titer increase ranged from 51 percent (against A/Hong Kong/68), 69 (against A/Hong Kong/71), 63 (against A/England/72) to 83 percent (against B/Iowa/69). Persons with high prevaccination titers failed to yield postvaccination antibody titer increase (table 1). Antibody titer increase measured against the neuraminidase of A/England/72 virus was recorded in 60 percent and against the neuraminidase of B/Iowa/69 virus in 31 percent (table 2). Using the neuraminidase of the recombinant strain (A/Bel/42 (H0)-A/Sing/57 (NS) as test antigen a significant titer increase in 32 percent of sera tested was found (table 2). The AN antibody titers against A/England/72 exceeded the titers against the A/Bel-A/Sing recombinant 3,67-5,42 fold. This finding was shown to be caused by additional reaction of anti-H3 antibody with A/England/72 virus resulting in steric hindrance of neuraminidase activity.